Pharmacoeconomic report: Dapagliflozin (Forxiga) : (AstraZeneca Canada Inc.) : indication: heart failure with reduced ejection fraction
For patients in New York Heart Association (NYHA) class II, the incremental cost-effectiveness ratio (ICER) for dapagliflozin plus standard therapy (DAPA + ST) versus standard therapy (ST) is $8,760 per quality-adjusted life-year (QALY). For patients in class III or IV, DAPA + ST is dominated by ST:...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, 2021
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references